MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Friday, May 19, 2017

Remyelination Candidate Opicinumab Failed in Phase 2 Trial in MS, But Biogen Won’t Give Up


May 2017

Although a Phase 2b trial of the remyelination drug candidate opicinumab (also known as anti-LINGO-1 and BIIB033) failed to meet its primary goal of improving disability in relapsing and secondary progressive multiple sclerosis (MS), researchers believe the drug did cause “fairly strong” improvements.
The trial evaluated four doses of the treatment. Analyses indicated the two intermediate doses made patients better, while the highest and the lowest doses had no detectable effects.
Dr. Peter A. Calabresi, director of the Johns Hopkins Multiple Sclerosis Center, presented insights from the trial at the American Academy of Neurology (AAN) 2017 Annual Meeting, held April 22-28 in Boston. The study, “Efficacy Results from the Phase 2b SYNERGY Study: Treatment of Disabling Multiple Sclerosis with the Anti-LINGO-1 Monoclonal Antibody Opicinumab,” was part of a session on progressive MS therapeutics.


In the trial (NCT01864148) — called SYNERGY by opicinumab’s developer, Biogen — 418 participants were randomized to receive one of four opicinumab doses in combination with Avonex (interferon beta-1a), or placebo with Avonex; 334 of the 418 completed the study.
Opicinumab is believed to trigger remyelination by preventing the actions of LINGO-1 — a factor that suppresses myelination and axonal regeneration. In the trial, researchers measured the percentage of patients who improved during three months or more in the Expanded Disability Status Scale (EDSS), the 25-Foot Walk, the 9-Hole Peg Test and the 3-Second Paced Auditory Serial Addition Test.
At the beginning, participants were mildly to moderately disabled, with EDSS scores of 2 to 6.
According to the researchers, placebo-treated participants improved by 51.6 percent. Those in the highest-dose and lowest-dose groups saw estimated improvements of 51.1 and 41.2 percent, while patients receiving the intermediate doses seemed to benefit most from the treatment.
Those taking 10 mg of opicinumab per kilogram of body weight improved by 65.6 percent, while for the 30 mg/kg group, scores improved by 68.8 percent.
“The take-home message is that the very lowest and highest doses don’t appear to do anything, but that we saw a fairly strong signal in the intermediate doses,” Calabresi, an associate professor of neurology at Johns Hopkins University, said in an AAN update in Neurology Today.


::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides Multiple Sclerosis education, information, resources and services that will benefit many affected by MS. 
SUBSCRIBE to our MS Learning Channel on YouTube: www.youtube.com/msviewsandnews
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

No comments: